OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/730,174

DATE: 01/26/2002
TIME: 13:53:51

Input Set : N:\EBONY'S\ES.txt
Output Set: N:\CRF3\01262002\I730174.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: R.J. ZAHRADNIK
W--> 4 <120> TITLE OF INVENTION: ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES HAVING A
W--> 5 SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1 84
W--> 6 <130> FILE REFERENCE: IMUNE-001A
W--> 7 <140> CURRENT APPLICATION NUMBER: 09/730,174
C--> 8 <141> CURRENT FILING DATE: 2002-01-09
E--> 8 <160> NUMBER OF SEQ ID: 12

See following pages

ERRORED SEQUENCES

10 <210> SEQ ID NO: 1
11 <211> LENGTH: 11
12 <212> TYPE: PRT
13 <213> ORGANISM: ARTIFICIAL SEQUENCE
W--> 14 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
W--> 14 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
15 <223> OTHER INFORMATION:
W--> 16 <400> SEQUENCE: 001; VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY
E--> 16 001; VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY
18 <210> SEQ ID NO: 2
19 <211> LENGTH: 11
20 <212> TYPE: PRT
21 <213> ORGANISM: ARTIFICIAL SEQUENCE
W--> 22 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
W--> 22 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
23 <223> OTHER INFORMATION:
W--> 24 <400> SEQUENCE: 002; VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY
E--> 24 002; VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY
26 <210> SEQ ID NO: 3
27 <211> LENGTH: 12
28 <212> TYPE: PRT
29 <213> ORGANISM: ARTIFICIAL SEQUENCE
W--> 30 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
W--> 30 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
31 <223> OTHER INFORMATION:
W--> 32 <400> SEQUENCE: 003; SER VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY
E--> 32 003; SER VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY
34 <210> SEQ ID NO: 4
35 <211> LENGTH: 12
36 <212> TYPE: PRT
37 <213> ORGANISM: ARTIFICIAL SEQUENCE
W--> 38 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES

09/730,174 *2*

~~SEQUENCE LISTING~~

<110> R.J. ZAHRADNIK
<120> ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES HAVING A SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1 84
<130> IMUNE-001A
<140> 09/730,174
<160> 12

<141> ← insert this numeric identifier and response

<210> 1
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE
<220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
<223>
<400> 001 VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY

move explanation to <223> line; delete; insert hard return; move amino acids to line below <400>
1 5 10

<210> 2
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE
<220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
<223>
<400> 002 VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY

number the amino acids under every 5 amino acids (DO NOT use TAB codes)
hard return
1 5 10

<210> 3
<211> 12
<212> PRT
<213> ARTIFICIAL SEQUENCE
<220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
<223>
<400> 003 SER VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY

hard return
1 5 10

<210> 4
<211> 12
<212> PRT
<213> ARTIFICIAL SEQUENCE
<220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
<223>
<400> 4 SER VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY

hard return
1 5 10

<210> 5
<211> 12
<212> PRT
<213> ARTIFICIAL SEQUENCE
<220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
<223>
<400> 5 ALA VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY

hard return
1 5 10

<210> 6
<211> 12
<212> PRT
<213> ARTIFICIAL SEQUENCE
<220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES
<223>
<400> 6 ALA VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY

hard return
1 5 10

DO NOT insert any response to <220>. <220> is a "header" only.

Use upper-case letter for the initial letter of amino acid e.g. Val Ser Glu Ile Gln not VAL SER GLU

(sample of global errors)

Please consult sample sequence listing (attached) for valid format

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001
<141> 1998-12-31

<150> US 08/999,999
<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.

<220>
<221> CDS
<222> (279)...(389)

<300>
<301> Doe, Richard
<302> Isolation and Characterization of a Gene Encoding a Protease from Paramecium sp.
<303> Journal of Genes
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400> 1

agctgtagtc attcctgtgt cctcttctct ctgggcttct caccctgcta atcagatctc 60

agggagagtg tcttgaccct cctctgcctt tgcagcttca caggcaggca ggcaggcagc 120

tgatgtggca attgctggca gtgtrracagg ccttccagcc aggcttaggg tgggttccgc 180

cgcggcgcgg cggccccctc cgcgctcctc tcgcgcctct ctctcgctct cctctcgctc 240

Please consult

Appendix 3, page 2

```
ggacctgatt  aggtgagcag  gaggaggggg  cagttagc        atg  gtt  tca  atg  ttc  agc   296
                                                    Met  Val  Ser  Met  Phe  Ser
                                                     1                   5

ttg  tct  ttc  aaa  tgg  cct  gga  ttt  tgt  ttg  ttt  gtt  tgt  ttg  ttc  caa   344
Leu  Ser  Phe  Lys  Trp  Pro  Gly  Phe  Cys  Leu  Phe  Val  Cys  Leu  Phe  Gln
               10                       15                  20

tgt  ccc  aaa  gtc  ctc  ccc  tgt  cac  tca  tca  ctg  cag  ccg  aat  ctt        389
Cys  Pro  Lys  Val  Leu  Pro  Cys  His  Ser  Ser  Leu  Gln  Pro  Asn  Leu
          25                       30                  35
```

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2

Met	Val	Ser	Met	Phe	Ser	Leu	Ser	Phe	Lys	Trp	Pro	Gly	Phe	Cys	Leu
1				5					10					15	

Phe	Val	Cys	Leu	Phe	Gln	Cys	Pro	Lys	Val	Leu	Pro	Cys	His	Ser	Ser
			20					25					30		

Leu	Gln	Pro	Asn	Leu
		35		

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3

Met	Val	Asn	Leu	Glu	Pro	Met	His	Thr	Glu	Ile
1				5					10	

<210> 4
<400> 4
000

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO: #	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	se was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	O
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	O
<302>	Title		O
<303>	Journal		O
<304>	Volume		O
<305>	Issue		O
<306>	Pages		O
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	O
<308>	Database Accession Number	Accession number assigned by database including database name	O
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	O
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	O

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.824 is revised to read as follows:

1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.821(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;

0590
0622

BIOTECHNOLOGY SYSTEMS BRANCH



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/730,174
Source: OIPE
Date Processed by STIC: 1/26/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there i a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<**http://www.uspto.gov/ebc/efs/downloads/documents.htm**> , **EFS Submission User Manual** - ePAVE)
2. **U.S. Postal Service:** U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name. Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
   Or
   U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service, or other delivery service to:** U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002